Skyai, Inc. quarterly report, Q3 FY2026

SkyAI, Inc. — Form 10-Q Summary

Reporting period: Quarter and nine months ended September 30, 2026. Filed November 6, 2026. The financial statements are unaudited.

Business context

SkyAI has shifted from medical-device manufacturing toward a digital-asset treasury strategy and, in May 2026, announced plans to build an AI-enabled “agentic finance” platform. It discontinued syringe manufacturing in October 2025; its remaining medical-device activity is sales and distribution. After quarter-end, the Company sold its SOL holdings and said it does not intend to repurchase SOL, leaving the AI platform as its stated strategic focus.

Financial results and position

  • Revenue: Third-quarter product revenue was zero, versus $68,040 a year earlier. Nine-month product revenue was $192,780, down from $204,120. Net staking revenue was $2.55 million for the quarter and $8.01 million year to date, compared with $2.21 million in each 2025 comparison period.
  • Profit/loss: Third-quarter net income was $84.93 million, versus a $105.33 million loss in 2025. The 2026 profit was primarily driven by a $90.53 million unrealized gain on digital commodities. Nine-month net loss was $24.59 million, compared with a $99.85 million loss in 2025.
  • Margins and costs: Product gross loss was $294,026 year to date, including a $284,228 inventory reserve. Third-quarter product gross margin was zero. Nine-month SG&A was $12.81 million; related-party consulting expense was $7.11 million; R&D was $1.05 million.
  • Cash flow: Operating cash use was $9.15 million for the first nine months. Investing activities provided $12.44 million, mainly from SOL sales; financing activities used $6.20 million, including margin-loan repayment and share repurchases. Cash declined from $10.38 million at year-end 2025 to $7.48 million at September 30, 2026.
  • Liquidity and debt: September 30 current assets were $12.02 million, including $3.05 million of payment stablecoins; current liabilities were $2.65 million. Total liabilities were $2.80 million and stockholders’ equity was $241.16 million. The Company reported no debt at quarter-end; its $3.08 million margin loan was repaid in February 2026.
  • Digital assets: At quarter-end, the Company held 2,002,683 SOL with a reported fair value of $231.43 million and cost basis of $378.20 million. Management estimated a hypothetical 10% SOL price movement would affect quarterly pretax income by approximately $23.1 million.

Material changes versus comparable periods

  • The third-quarter earnings reversal largely reflects digital-asset price movements: unrealized gains were $90.53 million in Q3 2026 versus $14.86 million in Q3 2025. Nine-month 2026 results also included $17.53 million of realized digital-asset losses, versus a $635,000 realized gain in 2025.
  • The 2025 comparative periods included a $101.33 million related-party warrant issuance expense and losses from discontinued operations. These items materially affect year-over-year comparisons.
  • Year-to-date staking revenue rose as the treasury strategy operated for a longer period. Product revenue remained small, while software-related R&D began in 2026.

Outlook, subsequent events, and risks

  • Post-quarter SOL sale: In October 2026, SkyAI sold approximately 2.0 million SOL for net proceeds of about $215 million. The reported realized loss was approximately $163 million; about $147 million had already been recorded as unrealized at September 30, and the Company expects an additional loss of approximately $16 million in Q4.
  • Tender offer: The amended offer was scheduled to expire November 12, 2026, unless extended or withdrawn. It offers $3.00 per common share and certain pre-funded and strategic warrants (less exercise price), and $0.17 per stapled warrant. If all securities sought are tendered, the Company expects to pay approximately $214.3 million from cash on hand, with no financing condition. Following SOL liquidation and conversion of USDC, the Company reported cash of approximately $224 million. The offer’s completion and final cash impact were not established in this filing.
  • Management said it expects to fund AI-platform development and working capital through equity issuance and/or other traditional financing until operations provide sufficient cash. It intends to maintain adequate liquid resources. No quantified revenue, earnings, or cash-flow guidance was provided.
  • Key risks include execution of an unproven strategic pivot, potential future financing and dilution, stock-price volatility, and the prior exposure of earnings to digital-asset prices. The Company also has a 20-year related-party consulting agreement with liquidated-damages provisions if terminated in specified circumstances.
  • The consultant, Sol Edge Limited, is controlled by the brother of the Company’s Chief Investment Officer and director. Management reported effective disclosure controls; the filing reported no legal proceedings.

Important facts for investors to verify

  • Whether the tender offer closed, how many shares and warrants were accepted, and the resulting cash balance, share count, and liquidity after payment.
  • The final accounting and cash impact of the October SOL sale, including the expected Q4 loss and any related transaction costs.
  • Progress, funding needs, commercialization plans, and potential revenue sources for the AI finance platform; no operating forecast is provided.
  • The scope, fee calculations, termination exposure, and governance oversight of the related-party consulting arrangement.
  • Potential dilution from outstanding warrants and options. The filing reports 85.38 million warrants outstanding at September 30 and 50.85 million common shares issued and outstanding as of November 2; confirm the treatment of securities affected by the tender offer.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.